135
Participants
Start Date
October 31, 2019
Primary Completion Date
May 19, 2022
Study Completion Date
May 19, 2022
MTPS9579A
MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.
Placebo
Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
Clinica Providencia (Inverconsult Sociedad Anonima), Lima
Research Center for Medical Studies RCMS, Berlin
Temple University Hospital, Philadelphia
Spartanburg Medical Research, Spartanburg
Pneumologicum, Hanover
Florida Pulmonary Research Institute, LLC, Winter Park
Florida Ctr-Allergy & Asthma, Miami
SMO.MD GmbH, Zentrum für klinische Studien, Magdeburg
Toledo Inst of Clin Research, Toledo
IKF Pneumologie, Frankfurt am Main
OK Clinical Research, Edmond
Kern Research, Bakersfield
Allergy & Asthma Medical Group of the Bay Area, Walnut Creek
Fundacion Cidea, Buenos Aires
Centro Médico Dra. Cristina de Salvo, Buenos Aires
CARE - Centro de Alergia y Enfermedades Respiratorias, CABA
Centro Respiratorio Quilmes, Quilmes
BAG Prof Dr G Hoheisel Dr A Bonitz, Leipzig
Clinica Ricardo Palma; THORAX, Lima
Centrum Medycyny Oddechowej Robert M. Mróz, Bialystok
Centrum Medyczne ALL-MED, Krakow
Malopolskie Centrum Alergologii, Krakow
SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi, Lodz
Ostrowieckie Centrum Medyczne Spolka Cywilna Anna Olec-Cudzik; Krzysztof Cudzik, Ostrowiec Swietokrzysk
Centrum Alergologii Teresa Hofman, Poznan
PULMAG Grzegorz Gasior Marzena Kociolek Spolka Cywilna, Sosnowiec
ALL-MED Specjalistyczna Opieka Medyczna, Wroclaw
Lead Sponsor
Genentech, Inc.
INDUSTRY